Validation of the revised international prognostic scoring system in treated patients with myelodysplastic syndromes

American Journal of Hematology

Volumn 88, Issue 7, 2013, Pages 566-570

  Mishra, Asmita ^a   Corrales Yepez, Maria ^a   Ali, Najla Al ^a   Kharfan Dabaja, Mohamed ^a   Padron, Eric ^a   Zhang, Ling ^a   Epling Burnette, Pearlie K ^a   Pinilla Ibarz, Javier ^a   Lancet, Jeffrey E ^a   List, Alan F ^a   Komrokji, Rami S ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE;

ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; LOW RISK POPULATION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; RETROSPECTIVE STUDY; VALIDATION STUDY;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PRACTICE GUIDELINES AS TOPIC; RESEARCH DESIGN; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TRANSPLANTATION, HOMOLOGOUS;

EID: 84879406390     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23454     Document Type: Article

References (16)

1. Bennett JM, Komrokji R, Kouides P. The myelodysplastic syndromes. In: Abeloff MD, Armitage JO, Niederhuber JE, editors. Clinical Oncology. New York: Churchill Livingstone; 2004. pp 2849-2881.
2. Komrokji RS, Zhang L, Bennett JM. Myelodysplastic syndromes classification and risk stratification. Hematol Oncol Clin North Am 2010;24:443-457.
3. Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079-2088.
4. NCCN Clinical Practice Guidelines in Oncology. Myelodysplastic Syndromes (Version 2, 2013). Accessed December 16, 2012. //www.nccn.org/professionals/physician_gls/f_guidelines.asp#mds.
5. Greenberg P, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood 2012;120:2454-2465.
6. Kantarjian H, O'Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008;113:1351-1361.
7. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study. Lancet Oncol 2009;10:223-232.
8. Malcovati L, Della Porta M, Pascutto C, et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: A basis for clinical decision- making. J Clin Oncol 2005;23:7594-7603.
9. Schanz J, Steidl C, Fonatsch C, et al. Coalesced multicentric analysis of 2, 351 patients with myelodysplastic syndromes indicates an underestimation of poor-risk cytogenetics of myelodysplastic syndromes in the international prognostic scoring system. J Clin Oncol 2011;29:1963-1970.
10. Malcovati L, Germing U, Kuendgen A, et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007;25:3503-3510.
11. Larson RA. Therapy-related myeloid neoplasms. Haematologica 2009;94:454-459.
12. Germing U, Kundgen A, Gattermann N. Risk assessment in chronic myelomonocytic leukemia (CMML). Leuk Lymphoma 2004;45:1311-1318.
13. Ades, L, Lamarque M, Raynaud S, et al. Revised-IPSS (IPSS-R) is a powerful tool to evaluate the outcome of MDS patient treated with azacitidine (AZA): The Groupe Francophone Des Myelodysplasies (GFM) Experience. Blood 2012;120:422 (abstr).
14. Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: Delayed for low-risk myelodysplasia is associated with improved outcome. Blood 2004;104:579-585.
15. Fan YS, editor. Methods in Molecular Biology. Molecular Cytogenetics: Protocols and Applications, Vol. 2. Totowa, NJ: Humana Press; 2002.
16. Bejar R, Stevenson K, Abdel-Wahab O, et al. Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 2011;364:2496-2506.